• WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Quality Principles
    • How we work
    • Partner
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • PK/PD
    • Proof of Concept
    • Biosimilars
    • Vaccines
    • Bioequivalence
  • SERVICES
    • Development Consulting
    • Regulatory Consulting
    • Medical Writing
    • Data Management
    • Statistics
    • Multi-Site Service
    • Bioanalytics
  • PATIENT TRIALS
    • Diabetes
    • Obesity and Metabolism
    • Hypertension, Lipids, Inflammation, Endothelial Dysfunction
    • NAFLD/NASH
    • Dermatology
    • Endometriosis
    • Polycystic Ovary Syndrome
    • Medical Device Studies
    • Hemostaseology
    • Hepatology
    • Renal Impairment
    • Your individual request
  • SCIENCE
    • Our approach
    • Publications
  • CAREER
  • NEWS
  • WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Quality Principles
    • How we work
    • Partner
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • PK/PD
    • Proof of Concept
    • Biosimilars
    • Vaccines
    • Bioequivalence
  • SERVICES
    • Development Consulting
    • Regulatory Consulting
    • Medical Writing
    • Data Management
    • Statistics
    • Multi-Site Service
    • Bioanalytics
  • PATIENT TRIALS
    • Diabetes
    • Obesity and Metabolism
    • Hypertension, Lipids, Inflammation, Endothelial Dysfunction
    • NAFLD/NASH
    • Dermatology
    • Endometriosis
    • Polycystic Ovary Syndrome
    • Medical Device Studies
    • Hemostaseology
    • Hepatology
    • Renal Impairment
    • Your individual request
  • SCIENCE
    • Our approach
    • Publications
  • CAREER
  • NEWS

Vildagliptin, a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.

Science 21. November 2022
ShareTwitterFacebookXingLinkedin
First published in Expert Opinion on Pharmacotherapy on 2014 Jun.Expert Opin Pharmacother. 2014 Jun;15(9):1299-313. doi: 10.1517/14656566.2014.920009 Authors: Forst T, Bramlage...
Read Article

Clinical overview of linagliptin, a dipeptidyl peptidase-4 inhibitor, in patients with Type 2 diabetes mellitus.

Science 21. November 2022
ShareTwitterFacebookXingLinkedin
First published in Expert Review of Endocrinology & Metabolism on 2013 Jan.Expert Rev Endocrinol Metab. 2013 Jan;8(1):21-35. doi: 10.1586/eem.12.69. Authors:...
Read Article

Cardiovascular benefits of GLP-1-based therapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control.

Science 9. November 2022
ShareTwitterFacebookXingLinkedin
First published in Experimental Diabetes Research on 2012Exp Diabetes Res. 2012;2012:635472. doi: 10.1155/2012/635472. Authors: Forst T, Weber MM, Pfützner A...
Read Article
QUICK LINKS
  • WE ARE
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • MANAGEMENT
  • EARLY PHASE
    • First-in-human
    • Cardiac safety
    • Infusion & injection
    • Inhalation
    • Pharmacology
    • Interaction
    • Consultancy
    • Medical Writing
    • Data Management
.
  • PATIENT TRIALS
    • Cardiometabolics
    • Dermatology
    • Women‘s Health
    • Hemostaseology
    • Hepatology
    • Pulmology
    • Renal Impairment
    • Vaccines
    • Your individual request
  • SCIENCE
  • WORK WITH US
EXPERTISE
  • Consultancy
  • Medical Writing
  • Early Phase
FACILITIES
  • Berlin
  • Kiel
  • Mannheim
  • Wuppertal
FÜR PROBANDEN
  • ÜBER STUDIEN
  • AN STUDIEN TEILNEHMEN
  • www.probandeninfo.de
LEGAL
  • PRIVACY
  • IMPRINT
  • DISCLAIMER
  • —
  • Career
    • CURRENT JOB
    • OPPORTUNITIES
Copyright © 2023 CRS. Experts. Early Phase. All rights reserved.